|CrossRef Text and Data Mining|
|Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.|
|Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors|
|Jee Hee Yoon, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang|
Endocrinol Metab. 2021;36(2):413-423. Published online April 6, 2021
Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
Absolute Eosinophil Count May be One of the Most Optimal Peripheral Blood Markers to Identify Risk of Immune-Related Adverse Events in Advanced Malignant Tumors Treated with PD-1/PD-L1 Inhibitors.
OR28-07 Increased BMI Is Associated With Anti PD-1/PD-L1-Induced Thyroid Immune-Related Adverse Events
Absolute Eosinophil Count May be an Optimal Peripheral Blood Marker to Identify Risk of Immune-Related Adverse Events in Advanced Malignant Tumors Treated with PD-1/PD-L1 Inhibitors: A Retrospective Analysis.
Immune-related adverse events (irAEs) with single-agent PD-1 vs PD-L1 inhibitors: A meta-analysis of 8,730 patients from clinical trials
Immune-related adverse events associated with PD-1/PD-L1 Inhibitors used as first-line treatment for advanced non-small cell lung cancer: a Bayesian network meta-analysis of randomized clinical trials
EP1.01-47 Thyroid Related Adverse Events Predict Survival in NSCLC Patients Receiving Anti-PD-1/ PD-L1 Therapy
CNS Radiation-Related Adverse Events in Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors
P09.29 Immune-Related Adverse Events and their Association with Effectiveness of PD-1/PD-L1 Inhibitors in NSCLC: A Real-World Study from China
Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors